Abstract
Purpose
In the last years, it has emerged the unmet need for imaging technologies able to accurately describe the biological and clinical heterogeneity of glioma, assess responsiveness to therapy, and predict patient outcomes. The increasing number of additional imaging parameters primarily derived from advanced Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET), the technical developments of hybrid PET/MRI scanners, and the use of artificial intelligence might be able to fill this gap. In the present narrative review, we analyzed the potential of radiomics features extracted from stand-alone PET/MRI or combined PET and MRI scanners in the assessment of glioma.
Methods
PubMed, Embase, and Web of Science were searched for articles published up to January 2021 using the following keywords: “PET/MRI AND glioma”, “PET/MRI AND glioblastoma”, “PET/MRI AND radiomics AND glioma”, “PET/MRI AND radiomics AND glioblastoma”. We included only original articles published in English reporting the use of PET/MRI or PET/MRI-derived radiomics features (extracted either from PET or MRI scanner or hybrid PET/MRI device) in patients with glioma.
Results
Published data suggest that hybrid PET/MRI may be superior to MRI-alone in differentiating low-grade vs. high-grade glioma, in detecting malignant transformation of LGG, and in the differential diagnosis between true recurrences from post-treatment changes. Moreover, PET/MRI could add helpful information for radiotherapy and surgery planning. Also, the rapid advancement in computer-based image analysis including artificial intelligence and radiomics has extended to PET imaging in the last years, with promising results particularly in the setting of preoperative imaging and in the post-treatment setting.
Conclusions
Published literature suggests a high potential for PET/MRI-derived radiomics. However, these results are based on small datasets and need to be further investigated in large prospective studies. Multidisciplinary efforts and multicenter collaborations will be essential to achieve these aims in the next future.
Similar content being viewed by others
References
la Fougère C, Suchorska B, Bartenstein P, Kreth FW, Tonn JC (2011) Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol 13:806–819. https://doi.org/10.1093/neuonc/nor054
Vartanian A, Singh SK, Agnihotri S, Jalali S, Burrell K, Aldape KD et al (2014) GBM’s multifaceted landscape: highlighting regional and microenvironmental heterogeneity. Neuro Oncol 16:1167–1175. https://doi.org/10.1093/neuonc/nou035
Mazurowski MA (2015) Radiogenomics: what it is and why it is important. J Am Coll Radiol 12:862–866. https://doi.org/10.1016/j.jacr.2015.04.019
Quartuccio N, Laudicella R, Vento A, Pignata S, Mattoli MV, Filice R et al (2020) The additional value of (18)F-FDG PET and MRI in patients with glioma: a review of the literature from 2015 to 2020. Diagnostics (Basel, Switzerland) 10:357. https://doi.org/10.3390/diagnostics10060357
Marner L, Henriksen OM, Lundemann M, Larsen VA, Law I (2017) Clinical PET/MRI in neurooncology: opportunities and challenges from a single-institution perspective. Clin Transl Imaging 5:135–149. https://doi.org/10.1007/s40336-016-0213-8
Deuschl C, Goericke S, Grueneisen J, Sawicki LM, Goebel J, El Hindy N et al (2016) Simultaneous 11C-methionine positron emission tomography/magnetic resonance imaging of suspected primary brain tumors. PLOS ONE 11:e0167596. https://doi.org/10.1371/journal.pone.0167596
Deuschl C, Moenninghoff C, Goericke S, Kirchner J, Köppen S, Binse I et al (2017) Response assessment of bevacizumab therapy in GBM with integrated 11C-MET-PET/MRI: a feasibility study. Eur J Nucl Med Mol Imaging 44:1285–1295. https://doi.org/10.1007/s00259-017-3661-0
Shaw TB, Jeffree RL, Thomas P, Goodman S, Debowski M, Lwin Z et al (2019) Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of glioma. J Med Imaging Radiat Oncol 63:650–656. https://doi.org/10.1111/1754-9485.12929
Verburg N, Koopman T, Yaqub MM, Hoekstra OS, Lammertsma AA, Barkhof F et al (2020) Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study. Neuro Oncol 22:412–422. https://doi.org/10.1093/neuonc/noz180
Deuschl C, Kirchner J, Poeppel TD, Schaarschmidt B, Kebir S, El Hindy N et al (2018) (11)C-MET PET/MRI for detection of recurrent glioma. Eur J Nucl Med Mol Imaging 45:593–601. https://doi.org/10.1007/s00259-017-3916-9
Karlberg A, Berntsen EM, Johansen H, Skjulsvik AJ, Reinertsen I, Dai HY et al (2019) 18F-FACBC PET/MRI in diagnostic assessment and neurosurgery of gliomas. Clin Nucl Med 44:550–559. https://doi.org/10.1097/RLU.0000000000002610
Brendle C, Hempel JM, Schittenhelm J, Skardelly M, Reischl G, Bender B et al (2018) Glioma grading by dynamic susceptibility contrast perfusion and (11)C-methionine positron emission tomography using different regions of interest. Neuroradiology 60:381–389. https://doi.org/10.1007/s00234-018-1993-5
Göttler J, Lukas M, Kluge A, Kaczmarz S, Gempt J, Ringel F et al (2017) Intra-lesional spatial correlation of static and dynamic FET-PET parameters with MRI-based cerebral blood volume in patients with untreated glioma. Eur J Nucl Med Mol Imaging 44:392–397. https://doi.org/10.1007/s00259-016-3585-0
Zhang K, Langen KJ, Neuner I, Stoffels G, Filss C, Galldiks N et al (2014) Relationship of regional cerebral blood flow and kinetic behaviour of O-(2-(18)F-fluoroethyl)-L-tyrosine uptake in cerebral gliomas. Nucl Med Commun 35:245–251. https://doi.org/10.1097/mnm.0000000000000036
Bisdas S, Ritz R, Bender B, Braun C, Pfannenberg C, Reimold M et al (2013) Metabolic mapping of gliomas using hybrid MR-PET imaging: feasibility of the method and spatial distribution of metabolic changes. Invest Radiol 48:295–301. https://doi.org/10.1097/RLI.0b013e31827188d6
Mauler J, Maudsley AA, Langen KJ, Nikoubashman O, Stoffels G, Sheriff S et al (2018) Spatial relationship of glioma volume derived from (18)F-FET PET and volumetric MR spectroscopy imaging: a hybrid PET/MRI study. J Nucl Med 59:603–609. https://doi.org/10.2967/jnumed.117.196709
Filss CP, Galldiks N, Stoffels G, Sabel M, Wittsack HJ, Turowski B et al (2014) Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. J Nucl Med 55:540–545. https://doi.org/10.2967/jnumed.113.129007
Henriksen OM, Larsen VA, Muhic A, Hansen AE, Larsson HBW, Poulsen HS et al (2016) Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [(18)F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience. Eur J Nucl Med Mol Imaging 43:103–112. https://doi.org/10.1007/s00259-015-3183-6
Jena A, Taneja S, Jha A, Damesha NK, Negi P, Jadhav GK et al (2017) Multiparametric evaluation in differentiating glioma recurrence from treatment-induced necrosis using simultaneous (18)F-FDG-PET/MRI: a single-institution retrospective study. Am J Neuroradiol 38:899–907. https://doi.org/10.3174/ajnr.A5124
Galldiks N, Langen KJ (2016) Amino acid PET—an imaging option to identify treatment response, posttherapeutic effects, and tumor recurrence? Front Neurol 7:120. https://doi.org/10.3389/fneur.2016.00120
Bobek-Billewicz B, Stasik-Pres G, Majchrzak H, Zarudzki L (2010) Differentiation between brain tumor recurrence and radiation injury using perfusion, diffusion-weighted imaging and MR spectroscopy. Folia Neuropathol 48:81–92
Pyka T, Hiob D, Preibisch C, Gempt J, Wiestler B, Schlegel J et al (2018) Diagnosis of glioma recurrence using multiparametric dynamic 18F-fluoroethyl-tyrosine PET-MRI. Eur J Radiol 103:32–37. https://doi.org/10.1016/j.ejrad.2018.04.003
Hojjati M, Badve C, Garg V, Tatsuoka C, Rogers L, Sloan A et al (2018) Role of FDG-PET/MRI, FDG-PET/CT, and dynamic susceptibility contrast perfusion mri in differentiating radiation necrosis from tumor recurrence in glioblastomas. J Neuroimaging Off J Am Soc Neuroimaging 28:118–125. https://doi.org/10.1111/jon.12460
Pyatigorskaya N, Sgard B, Bertaux M, Yahia-Cherif L, Kas A (2021) Can FDG-PET/MR help to overcome limitations of sequential MRI and PET-FDG for differential diagnosis between recurrence/progression and radionecrosis of high-grade gliomas? J Neuroradiol 48:189–194. https://doi.org/10.1016/j.neurad.2020.08.003
Lohmeier J, Bohner G, Siebert E, Brenner W, Hamm B, Makowski MR (2019) Quantitative biparametric analysis of hybrid (18)F-FET PET/MR-neuroimaging for differentiation between treatment response and recurrent glioma. Sci Rep 9:14603. https://doi.org/10.1038/s41598-019-50182-4
Lundemann M, Munck AF, Rosenschöld P, Muhic A, Larsen VA, Poulsen HS, Engelholm SA et al (2019) Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma. Eur J Nucl Med Mol Imaging 46:603–613. https://doi.org/10.1007/s00259-018-4180-3
Song S, Cheng Y, Ma J, Wang L, Dong C, Wei Y et al (2020) Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET/MR improves delineation of tumor spatial biodistribution in gliomas: a biopsy validation study. Eur J Nucl Med Mol Imaging 47:1458–1467. https://doi.org/10.1007/s00259-019-04656-2
Song S, Wang L, Yang H, Shan Y, Cheng Y, Xu L et al (2021) Static (18)F-FET PET and DSC-PWI based on hybrid PET/MR for the prediction of gliomas defined by IDH and 1p/19q status. Eur Radiol 31:4087–4096. https://doi.org/10.1007/s00330-020-07470-9
Fleischmann DF, Unterrainer M, Corradini S, Rottler M, Förster S, la Fougère C et al (2019) Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation. PLOS ONE 14:e0216111. https://doi.org/10.1371/journal.pone.0216111
Sogani SK, Jena A, Taneja S, Gambhir A, Mishra AK, D’Souza MM et al (2017) Potential for differentiation of glioma recurrence from radionecrosis using integrated (18)F-fluoroethyl-L-tyrosine (FET) positron emission tomography/magnetic resonance imaging: A prospective evaluation. Neurol India 65:293–301. https://doi.org/10.4103/neuroindia.NI_101_16
Barajas RF, Krohn KA, Link JM, Hawkins RA, Clarke JL, Pampaloni MH et al (2016) Glioma FMISO PET/MR imaging concurrent with antiangiogenic therapy: molecular imaging as a clinical tool in the burgeoning era of personalized medicine. Biomedicines. https://doi.org/10.3390/biomedicines4040024
Laudicella R, Comelli A, Stefano A, Szostek M, Crocè L, Vento A et al (2020) Artificial neural networks in cardiovascular diseases and its potential for clinical application in molecular imaging. Curr Radiopharm. https://doi.org/10.2174/1874471013666200621191259
Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures, they are data. Radiology 278:563–577. https://doi.org/10.1148/radiol.2015151169
Naqa IE (2014) The role of quantitative PET in predicting cancer treatment outcomes. Clin Trans Imaging 2:305–320. https://doi.org/10.1007/s40336-014-0063-1
O’Connor JP, Rose CJ, Waterton JC, Carano RA, Parker GJ, Jackson A (2015) Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin Cancer Res Off J Am Assoc Cancer Res 21:249–257. https://doi.org/10.1158/1078-0432.ccr-14-0990
Rubin MA (2015) Health: make precision medicine work for cancer care. Nature 520:290–291. https://doi.org/10.1038/520290a
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science (New York, NY) 321:1807–1812. https://doi.org/10.1126/science.1164382
Eichinger P, Alberts E, Delbridge C, Trebeschi S, Valentinitsch A, Bette S et al (2017) Diffusion tensor image features predict IDH genotype in newly diagnosed WHO grade II/III gliomas. Sci Rep 7:13396. https://doi.org/10.1038/s41598-017-13679-4
Li Z, Wang Y, Yu J, Guo Y, Cao W (2017) Deep learning based radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma. Sci Rep 7:5467. https://doi.org/10.1038/s41598-017-05848-2
Zhang B, Chang K, Ramkissoon S, Tanguturi S, Bi WL, Reardon DA et al (2017) Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol 19:109–117. https://doi.org/10.1093/neuonc/now121
Lohmann P, Lerche C, Bauer EK, Steger J, Stoffels G, Blau T et al (2018) Predicting IDH genotype in gliomas using FET PET radiomics. Sci Rep 8:13328. https://doi.org/10.1038/s41598-018-31806-7
Haubold J, Demircioglu A, Gratz M, Glas M, Wrede K, Sure U et al (2020) Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric (18)F-FET PET-MRI and MR fingerprinting. Eur J Nucl Med Mol Imaging 47:1435–1445. https://doi.org/10.1007/s00259-019-04602-2
Kebir S, Weber M, Lazaridis L, Deuschl C, Schmidt T, Monninghoff C et al (2019) Hybrid 11C-MET PET/MRI combined with “machine learning” in glioma diagnosis according to the revised glioma WHO classification 2016. Clin Nucl Med 44:214–220. https://doi.org/10.1097/rlu.0000000000002398
Li L, Mu W, Wang Y, Liu Z, Liu Z, Wang Y et al (2019) A non-invasive radiomic method using (18)F-FDG PET predicts isocitrate dehydrogenase genotype and prognosis in patients with glioma. Front Oncol 9:1183. https://doi.org/10.3389/fonc.2019.01183
Gevaert O, Mitchell LA, Achrol AS, Xu J, Echegaray S, Steinberg GK et al (2015) Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features. Radiology 276:313. https://doi.org/10.1148/radiol.2015154019
Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A et al (2013) Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med 54:19–26. https://doi.org/10.2967/jnumed.112.107375
Papp L, Pötsch N, Grahovac M, Schmidbauer V, Woehrer A, Preusser M et al (2018) Glioma survival prediction with combined analysis of in vivo (11)C-MET PET features, Ex Vivo features, and patient features by supervised machine learning. J Nucl Med 59:892–899. https://doi.org/10.2967/jnumed.117.202267
Kong Z, Li J, Liu Z, Liu Z, Zhao D, Cheng X et al (2019) Radiomics signature based on FDG-PET predicts proliferative activity in primary glioma. Clin Radiol. https://doi.org/10.1016/j.crad.2019.06.019
Wang K, Qiao Z, Zhao X, Li X, Wang X, Wu T et al (2020) Individualized discrimination of tumor recurrence from radiation necrosis in glioma patients using an integrated radiomics-based model. Eur J Nucl Med Mol Imaging 47:1400–1411. https://doi.org/10.1007/s00259-019-04604-0
Muzi M, Wolsztynski E, Fink JR, O’Sullivan JN, O’Sullivan F, Krohn KA et al (2020) Assessment of the prognostic value of radiomic features in (18)F-FMISO PET imaging of hypoxia in postsurgery brain cancer patients: secondary analysis of imaging data from a single-center study and the multicenter ACRIN 6684 trial. Tomography (Ann Arbor, Mich) 6:14–22. https://doi.org/10.18383/j.tom.2019.00023
Kong Z, Lin Y, Jiang C, Li L, Liu Z, Wang Y et al (2019) (18)F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma. Cancer Imaging 19:58. https://doi.org/10.1186/s40644-019-0246-0
Yu P, Ning J, Xu B, Liu J, Dang H, Lin M et al (2019) Histogram analysis of 11C-methionine integrated PET/MRI may facilitate to determine the O6-methylguanylmethyltransferase methylation status in gliomas. Nucl Med Commun 40:850–856. https://doi.org/10.1097/mnm.0000000000001039
Hope TA, Fayad ZA, Fowler KJ, Holley D, Iagaru A, McMillan AB et al (2019) Summary of the first ISMRM-SNMMI workshop on PET/MRI: applications and limitations. J Nucl Med 60:1340–1346. https://doi.org/10.2967/jnumed.119.227231
Qian J, Herman MG, Brinkmann DH, Laack NN, Kemp BJ, Hunt CH et al (2020) Prediction of MGMT status for glioblastoma patients using radiomics feature extraction from (18)F-DOPA-PET imaging. Int J Radiat Oncol Biol Phys 108:1339–1346. https://doi.org/10.1016/j.ijrobp.2020.06.073
Imani F, Boada FE, Lieberman FS, Davis DK, Mountz JM (2014) Molecular and metabolic pattern classification for detection of brain glioma progression. Eur J Radiol 83:e100–e105. https://doi.org/10.1016/j.ejrad.2013.06.033
Hotta M, Minamimoto R, Miwa K (2019) 11C-methionine-PET for differentiating recurrent brain tumor from radiation necrosis: radiomics approach with random forest classifier. Sci Rep 9:15666. https://doi.org/10.1038/s41598-019-52279-2
Kebir S, Weber M, Lazaridis L, Deuschl C, Schmidt T, Mönninghoff C et al (2019) Hybrid 11C-MET PET/MRI combined with “machine learning” in glioma diagnosis according to the revised glioma WHO classification 2016. Clin Nucl Med 44:214–220. https://doi.org/10.1097/rlu.0000000000002398
Liesche F, Lukas M, Preibisch C, Shi K, Schlegel J, Meyer B et al (2019) (18)F-Fluoroethyl-tyrosine uptake is correlated with amino acid transport and neovascularization in treatment-naive glioblastomas. Eur J Nucl Med Mol Imaging 46:2163–2168. https://doi.org/10.1007/s00259-019-04407-3
Rogasch JMM, Albers J, Steinkrüger FL, Lukas M, Wedel F, Amthauer H et al (2019) Point spread function reconstruction for integrated 18F-FET PET/MRI in patients with glioma: does it affect SUVs and respective tumor-to-background ratios? Clin Nucl Med 44:e280–e285. https://doi.org/10.1097/rlu.0000000000002423
Sacconi B, Raad RA, Lee J, Fine H, Kondziolka D, Golfinos JG et al (2016) Concurrent functional and metabolic assessment of brain tumors using hybrid PET/MR imaging. J Neurooncol 127:287–293. https://doi.org/10.1007/s11060-015-2032-6
Seligman L, Kovanlikaya I, Pisapia DJ, Naeger DM, Magge R, Fine HA et al (2019) Integrated PET-MRI for glioma surveillance: perfusion-metabolism discordance rate and association with molecular profiling. Am J Roentgenol 212:883–891. https://doi.org/10.2214/ajr.18.20531
Ferda J, Ferdová E, Hes O, Mraček J, Kreuzberg B, Baxa J (2017) PET/MRI: multiparametric imaging of brain tumors. Eur J Radiol 94:A14-a25. https://doi.org/10.1016/j.ejrad.2017.02.034
Laudicella R, Baratto L, Minutoli F, Baldari S, Iagaru A (2020) Malignant cutaneous melanoma: updates in PET imaging. Curr Radiopharm 13:14–23. https://doi.org/10.2174/1874471012666191015095550
Fink JR, Muzi M, Peck M, Krohn KA (2015) Multimodality brain tumor imaging: MR imaging, PET, and PET/MR imaging. J Nucl Med 56:1554–1561. https://doi.org/10.2967/jnumed.113.131516
Aasheim LB, Karlberg A, Goa PE, Håberg A, Sørhaug S, Fagerli UM et al (2015) PET/MR brain imaging: evaluation of clinical UTE-based attenuation correction. Eur J Nucl Med Mol Imaging 42:1439–1446. https://doi.org/10.1007/s00259-015-3060-3
Funding
This study was partially sustained by a grant from the “Sick Foundation” and “Jimmy Wirth Foundation”.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
All the authors declare that they have no conflict of interest related to this review.
Ethics approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Consent to participate
For this type of study, formal consent is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Laudicella, R., Bauckneht, M., Cuppari, L. et al. Emerging applications of imaging in glioma: focus on PET/MRI and radiomics. Clin Transl Imaging 9, 609–623 (2021). https://doi.org/10.1007/s40336-021-00464-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40336-021-00464-7